Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT04545710
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Abemaciclib — DRUG
    Abemaciclib 150mg BID
  • Osimertinib — DRUG
    Osimertinib 80mg daily

Study Details

Lung cancer is the leading cause of cancer deaths. Advances in the systemic treatment of non-small cell lung cancer (NSCLC) have increased survival in metastatic EGFR-mutated NSCLC. However resistance to therapy can develop.

Key Dates

Start date
Nov 21, 2020
Status verified
Aug 2024
Primary completion
Dec 1, 2025
Completion
Dec 1, 2026

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm, POC
    Single arm, POC Safety and Efficacy Osimertinib 80 mg QD Abemaciclib 150mg BID

Primary Outcome Measure

Progression Free Survival at 6 months [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCSD Moores Cancer CenterLa JollaCalifornia92093-

Find similar trials in La Jolla, CA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
UCSD Moores Cancer Center· La Jolla, CA

Related Studies